114 related articles for article (PubMed ID: 38383241)
21. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.
McKay RR; Kroeger N; Xie W; Lee JL; Knox JJ; Bjarnason GA; MacKenzie MJ; Wood L; Srinivas S; Vaishampayan UN; Rha SY; Pal SK; Donskov F; Tantravahi SK; Rini BI; Heng DY; Choueiri TK
Eur Urol; 2014 Mar; 65(3):577-84. PubMed ID: 23962746
[TBL] [Abstract][Full Text] [Related]
22. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P
BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209
[TBL] [Abstract][Full Text] [Related]
23. Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor.
Yukihiro K; Teishima J; Goto K; Aoki G; Sekino Y; Hayashi T; Hasegawa Y; Mita K; Kato M; Kajiwara M; Shigeta M; Maruyama S; Kadonishi Y; Fujiwara S; Hinata N
Urol Oncol; 2022 Oct; 40(10):455.e11-455.e18. PubMed ID: 35851184
[TBL] [Abstract][Full Text] [Related]
24. Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.
Rini BI; Hutson TE; Figlin RA; Lechuga MJ; Valota O; Serfass L; Rosbrook B; Motzer RJ
Clin Genitourin Cancer; 2018 Aug; 16(4):298-304. PubMed ID: 29853320
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Factors for Survival of Patients With Synchronous or Metachronous Brain Metastasis of Renal Cell Carcinoma.
Choi SY; Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
Clin Genitourin Cancer; 2017 Dec; 15(6):717-723. PubMed ID: 28552571
[TBL] [Abstract][Full Text] [Related]
26. Local salvage therapy for late (≥2 years) metastatic and local relapse of renal cell cancer is a potentially curative treatment irrespective of the site of recurrence.
Grüllich C; Vallet S; Hecht C; Duensing S; Hadaschik B; Jäger D; Hohenfellner M; Pahernik S
Urol Oncol; 2016 May; 34(5):238.e9-17. PubMed ID: 26739671
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Impact of Bone Metastasis on Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated by First Line Tyrosine Kinase Inhibitors: A Propensity-Score Matching Analysis.
Kang M; Choi J; Kim J; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Park SH; Song C; Seo SI
J Cancer; 2020; 11(24):7202-7208. PubMed ID: 33193883
[No Abstract] [Full Text] [Related]
28. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
29. [Clinical and pathological analysis of renal cell carcinoma bone metastasis].
Huang ZX; DU YQ; Zhang XP; Liu SJ; Xu T
Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Oct; 50(5):811-815. PubMed ID: 30337740
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of palliative surgery for bone metastasis of metastatic renal cell carcinoma in the era of targeted therapy.
Hara H; Kawamoto T; Fukase N; Sawada R; Fujiwara S; Yahiro S; Miyamoto T; Terakawa T; Mifune Y; Hoshino Y; Kakutani K; Matsumoto T; Matsushita T; Niikura T; Kuroda R; Akisue T
Eur J Surg Oncol; 2023 May; 49(5):928-933. PubMed ID: 36463006
[TBL] [Abstract][Full Text] [Related]
31. Comparison of outcomes for Hispanic and non-Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma Database.
Guram K; Huang J; Mouchati C; Abdallah N; Jani C; Navani V; Xie W; El Zarif T; Adib E; Gebrael G; Agarwal N; Li H; Labaki C; Labban M; Ruiz Morales JM; Choueiri TK; Chin Heng DY; Mittal A; Hansen AR; Rose BS; McKay RR
Cancer; 2024 Jun; 130(11):2003-2013. PubMed ID: 38297953
[TBL] [Abstract][Full Text] [Related]
32. External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.
Yekedüz E; Karakaya S; Ertürk İ; Tural D; Uçar G; Şentürk Öztaş N; Arıkan R; Hızal M; Küçükarda A; Sever ÖN; Arslan Ç; Can O; Kılıçkap S; Yazgan C; Karadurmuş N; Şendur MA; Çiçin İ; Demirci U; Özgüroğlu M; Öksüzoğlu B; Ürün Y
Clin Genitourin Cancer; 2023 Feb; 21(1):175-182. PubMed ID: 35970759
[TBL] [Abstract][Full Text] [Related]
33. The effectiveness of systemic therapies after surgery for metastatic renal cell carcinoma to the spine: a propensity analysis controlling for sarcopenia, frailty, and nutrition.
Massaad E; Saylor PJ; Hadzipasic M; Kiapour A; Oh K; Schwab JH; Schoenfeld AJ; Shankar GM; Shin JH
J Neurosurg Spine; 2021 Jun; 35(3):356-365. PubMed ID: 34171829
[TBL] [Abstract][Full Text] [Related]
34. Clinical Characteristics and Prognosis of Renal Cell Carcinoma With Spinal Bone Metastases.
Zhai J; Liu N; Wang H; Huang G; Man L
Front Oncol; 2021; 11():659779. PubMed ID: 34221976
[TBL] [Abstract][Full Text] [Related]
35. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.
Aldin A; Besiroglu B; Adams A; Monsef I; Piechotta V; Tomlinson E; Hornbach C; Dressen N; Goldkuhle M; Maisch P; Dahm P; Heidenreich A; Skoetz N
Cochrane Database Syst Rev; 2023 May; 5(5):CD013798. PubMed ID: 37146227
[TBL] [Abstract][Full Text] [Related]
36. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Chen X; Meng F; Jiang R
Front Oncol; 2021; 11():746976. PubMed ID: 34900692
[TBL] [Abstract][Full Text] [Related]
37. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
[TBL] [Abstract][Full Text] [Related]
38. Synchronous brain metastases as a poor prognosis factor in clear cell renal carcinoma: a strong argument for systematic brain screening.
Ruste V; Sunyach MP; Tanguy R; Jouanneau E; Schiffler C; Carbonnaux M; Moriceau G; Neidhardt EM; Boyle H; Robin S; Négrier S; Fléchon A
J Neurooncol; 2021 May; 153(1):133-141. PubMed ID: 33837880
[TBL] [Abstract][Full Text] [Related]
39. Serum Alpha1-Globulin as a Novel Prognostic Factor in Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
Chen X; Yao J; Liu L; Zheng W; Hu X; Zhu Y; Wang H; Guo J
Target Oncol; 2019 Apr; 14(2):187-195. PubMed ID: 30887420
[TBL] [Abstract][Full Text] [Related]
40. Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors.
Santoni M; Heng DY; Bracarda S; Procopio G; Milella M; Porta C; Matrana MR; Cartenì G; Crabb SJ; De Giorgi U; Basso U; Masini C; Calabrò F; Vitale MG; Santini D; Massari F; Galli L; Fornarini G; Ricotta R; Buti S; Zucali P; Caffo O; Morelli F; Carrozza F; Martignetti A; Gelibter A; Iacovelli R; Mosca A; Atzori F; Vau N; Incorvaia L; Ortega C; Scarpelli M; Lopez-Beltran A; Cheng L; Paolucci V; Graham J; Pierce E; Scagliarini S; Sepe P; Verzoni E; Merler S; Rizzo M; Sorgentoni G; Conti A; Piva F; Cimadamore A; Montironi R; Battelli N
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31905816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
